We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

HospiMedica

Download Mobile App
Recent News Medica 2024 AI Critical Care Surgical Techniques Patient Care Health IT Point of Care Business Focus

Study Reveals Limits of Pregnancy Testing

By HospiMedica staff writers
Posted on 15 Oct 2001
A study has demonstrated that around 10% of clinical pregnancies are undetectable on the first day of missed menses by an extremely sensitive assay for human chorionic gonadotropin (hCG). The researchers say this suggests that perhaps an even larger percentage of pregnancies are undetected by home test kits because of practical limitations and user error. The study was published in the October 10, 2001, issue of The Journal of the American Medical Association (JAMA).

Pregnancy cannot be detected before implantation. The study, which involved 221 women, found that pregnancy tests may not be accurate on the first day or so after a missed period because implantation had not yet occurred. Attachment occurs roughly nine days after fertilization but can range from six to 12 days because of the natural variability in ovulation. The researchers found that 10% of the embryo attachments—and hence new pregnancies—had not occurred by the day the women expected their periods to begin.

"These findings mean that if women were to buy a test kit, follow the directions, and test themselves on the first day of their expected periods, the test would be negative for many women, and they would not know that they'd become pregnant,” said Dr. Allen J. Wilcox, faculty member at the University of North Carolina at Chapel Hill (USA; www.unc.edu) and senior investigator of the study. "This is true even if their doctors had given them a blood test for pregnancy that day.”





Related Links:
JAMA

Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
New
Mammo 3D Performance Kits
Mammo 3D Performance Kits
New
Portable Patient Lift
Maxi Move

Latest Patient Care News

Portable Biosensor Platform to Reduce Hospital-Acquired Infections

First-Of-Its-Kind Portable Germicidal Light Technology Disinfects High-Touch Clinical Surfaces in Seconds

Surgical Capacity Optimization Solution Helps Hospitals Boost OR Utilization